Inventor · disambiguated record
Eric Steven Burak
Also filed as: BURAK ERIC · BURAK ERIC S · BURAK ERIC STEVEN
12 granted patents·18 pending applications·78 citations·filing 1997–2023
90Inventor score
Files withFUSION PHARMACEUTICALS INC11CENTRE FOR PROBE DEV AND COMMERCIALIZATION6GUILFORD PHARM INC4MELINTA SUBSIDIARY CORP3BURAK ERIC S2
Top patents by PatentIndex Score
30 records- 0192US10093741B1IGF-1R monoclonal antibodies and uses thereofFUSION PHARMACEUTICALS INC·Filed 2017·Granted Oct 9, 2018·20 cites·18 claims
- 0289US11191854B2Pharmacokinetic enhancements of bifunctional chelates and uses thereofCENTRE FOR PROBE DEV AND COMMERCIALIZATION·Filed 2018·Granted Dec 7, 2021·9 cites·16 claims
- 0384US11433148B2IGF-1R monoclonal antibodies and uses thereofCENTRE FOR PROBE DEV AND COMMERCIALIZATION·Filed 2018·Granted Sep 6, 2022·3 cites·40 claims
- 0478US11793895B2Residualizing linkers and uses thereofCENTRE FOR PROBE DEV AND COMMERCIALIZATION·Filed 2020·Granted Oct 24, 2023·1 cites·24 claims
- 0578US2024307368A1Antimicrobial compositionsMELINTA SUBSIDIARY CORP·Filed 2023·Application pending·0 cites
- 0675US9409896B2Sustained release pharmaceutical compositions comprising an antibacterial agentBURAK ERIC S·Filed 2011·Granted Aug 9, 2016·3 cites·15 claims
- 0775US6486151B2N-oxides of heterocyclic esters, amides, thioesters, and ketonesGUILFORD PHARM INC·Filed 2001·Granted Nov 26, 2002·5 cites·7 claims
- 0872US10758636B2Residualizing linkers and uses thereofCENTRE FOR PROBE DEV AND COMMERCIALIZATION·Filed 2014·Granted Sep 1, 2020·1 cites·1 claims
- 0972US6251892B1N-oxides of heterocyclic esters, amides, thioesters, and ketonesGUILFORD PHARM INC·Filed 2000·Granted Jun 26, 2001·4 cites·33 claims
- 1070US5846979AN-oxides of heterocyclic esters, amides, thioesters, and ketonesGUILFORD PHARM INC·Filed 1997·Granted Dec 8, 1998·22 cites·20 claims
- 1169US12138257B2Antimicrobial compositionsMELINTA SUBSIDIARY CORP·Filed 2019·Granted Nov 12, 2024·0 cites·20 claims
- 1269US2022265636A1Antimicrobial compositionsMELINTA SUBSIDIARY CORP·Filed 2021·Application pending·0 cites
- 1368US11446401B2Actinium-225 and checkpoint inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2019·Granted Sep 20, 2022·0 cites·1 claims
- 1468US2023270895A1Radioimmunoconjugates and checkpoint inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1566US2021290788A1Radioimmunoconjugates and dna damage and repair inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1665US2023052140A1Igf-1r monoclonal antibodies and uses thereofCENTRE FOR PROBE DEV AND COMMERCIALIZATION·Filed 2022·Application pending·0 cites
- 1763US2021290789A1Radioimmunoconjugates and checkpoint inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1862US2022054664A1Pharmacokinetic enhancements of bifunctional chelates and uses thereofCENTRE FOR PROBE DEV AND COMMERCIALIZATION·Filed 2021·Application pending·0 cites
- 1959US2025001019A1Methods of treating cancerFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2058US6054452AN-oxides of heterocyclic esters, amides, thioesters, and ketonesGUILFORD PHARM INC·Filed 1998·Granted Apr 25, 2000·10 cites·4 claims
- 2155US2024165280A1Methods for treatment of cancersFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2251US2024285818A1Radioimmunoconjugates and checkpoint inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2349US2016235736A1Antimicrobial compositionsMELINTA THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2448US2015165040A1Pharmaceutical Compositions of Oxazolidinone Antimicrobial AgentsMELINTA THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 2547US2012065186A1Antimicrobial compositionsLI DANPING·Filed 2011·Application pending·0 cites
- 2646US2021395281A1Macrocyclic chelates and uses thereofFUSION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2745US2023091468A1Sustained immunotherapyFUSION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2845US2012208857A1Pharmaceutical CompositionsBURAK ERIC S·Filed 2010·Application pending·0 cites
- 2942US2023201384A1Fgfr3-targeted radioimmunoconjugates and uses thereofFUSION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3037US2005203068A1Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering sameFiled 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →